Harpoon Therapeutics Stock Price, News & Analysis (NASDAQ:HARP) $9.67 -0.95 (-8.95%) (As of 03:44 PM ET) Add Compare Share Share Today's Range$9.51▼$11.5050-Day Range$3.29▼$12.9952-Week Range$3.11▼$33.55Volume187,591 shsAverage Volume70,955 shsMarket Capitalization$163.73 millionP/E RatioN/ADividend YieldN/APrice Target$29.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Harpoon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside202.9% Upside$29.50 Price TargetShort InterestHealthy1.90% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment1.22Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.93) to ($3.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector168th out of 953 stocksBiological Products, Except Diagnostic Industry20th out of 148 stocks 3.4 Analyst's Opinion Consensus RatingHarpoon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.50, Harpoon Therapeutics has a forecasted upside of 202.9% from its current price of $9.74.Amount of Analyst CoverageHarpoon Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.90% of the float of Harpoon Therapeutics has been sold short.Short Interest Ratio / Days to CoverHarpoon Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harpoon Therapeutics has recently increased by 7.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarpoon Therapeutics does not currently pay a dividend.Dividend GrowthHarpoon Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHarpoon Therapeutics has received a 76.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Harpoon Therapeutics is -0.61. Previous Next 4.0 News and Social Media Coverage News SentimentHarpoon Therapeutics has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Harpoon Therapeutics this week, compared to 1 article on an average week.Search Interest14 people have searched for HARP on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows5 people have added Harpoon Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harpoon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.01% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($1.93) to ($3.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harpoon Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harpoon Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarpoon Therapeutics has a P/B Ratio of 5.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harpoon Therapeutics Stock (NASDAQ:HARP)Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma. Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential. Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.Read More HARP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HARP Stock News HeadlinesDecember 6, 2023 | finance.yahoo.comImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLADecember 6, 2023 | americanbankingnews.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Given Consensus Recommendation of "Moderate Buy" by BrokeragesDecember 6, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 5, 2023 | finance.yahoo.comHarpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock?November 30, 2023 | finance.yahoo.comWall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to TradeNovember 30, 2023 | finance.yahoo.comIs it a Good Idea to Invest in Harpoon (HARP) Stock Now?November 21, 2023 | seekingalpha.comHarpoon: HPN328 Data In 1st Half Of 2024 Makes This A Must WatchNovember 21, 2023 | msn.comTD Cowen Initiates Coverage of Harpoon Therapeutics (HARP) with Outperform RecommendationDecember 6, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 15, 2023 | finance.yahoo.comFast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a BargainNovember 14, 2023 | finance.yahoo.comWall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?November 11, 2023 | msn.comHarpoon Therapeutics GAAP EPS of -$0.46, revenue of $4.54MNovember 9, 2023 | finance.yahoo.comHarpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 4, 2023 | markets.businessinsider.comOptimistic Financial Outlook and Promising Clinical Developments Drive Buy Rating for Bicycle TherapeuticsNovember 4, 2023 | markets.businessinsider.comBicycle Therapeutics: Strong Financial Standing and Promising Lead Assets Reinforce Buy RatingNovember 2, 2023 | finance.yahoo.comHarpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and ExpositionOctober 28, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Bicycle Therapeutics (BCYC), Abbott Labs (ABT) and VolitionRX (VNRX)October 25, 2023 | benzinga.comHarpoon Therapeutics Stock (NASDAQ:HARP), Analyst Ratings, Price Targets, PredictionsOctober 23, 2023 | markets.businessinsider.comHarpoon Therapeutics Announces Private Placement Of Up To $150 MlnOctober 23, 2023 | marketwatch.comHarpoon Therapeutics Shares Rise 39% After Positive HPN328 Trial DataOctober 23, 2023 | proactiveinvestors.comHarpoon Therapeutics stock soars on ‘promising’ lung cancer drug resultsOctober 23, 2023 | marketwatch.comHarpoon Therapeutics to Raise Up to $150 Million in Private PlacementOctober 23, 2023 | benzinga.comWhat's Going On With Harpoon Therapeutics Stock Monday?October 23, 2023 | msn.comHarpoon climbs on data for cancer drug (updated)October 23, 2023 | finance.yahoo.comHarpoon Therapeutics Announces Up to $150 Million Private PlacementOctober 21, 2023 | finance.yahoo.comHarpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023October 16, 2023 | finance.yahoo.comHarpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023See More Headlines Receive HARP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HARP CUSIPN/A CIK1708493 Webwww.harpoontx.com Phone(650) 443-7400FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$29.50 High Stock Price Target$45.00 Low Stock Price Target$13.00 Potential Upside/Downside+168.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($8.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,730,000.00 Net Margins-81.68% Pretax Margin-81.67% Return on Equity-893.55% Return on Assets-45.98% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$37.34 million Price / Sales4.98 Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book6.74Miscellaneous Outstanding Shares16,932,000Free Float14,054,000Market Cap$186.08 million OptionableNot Optionable Beta2.10 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Julie M. Eastland M.B.A. (Age 59)President, CEO, Secretary & Director Comp: $910.77kKey CompetitorsScilexNASDAQ:SCLXSemper Paratus AcquisitionNASDAQ:LGSTZura BioNASDAQ:ZURASutro BiopharmaNASDAQ:STROERYTECH PharmaNASDAQ:ERYPView All CompetitorsInsiders & InstitutionsKennedy Capital Management LLCSold 476,947 shares on 11/15/2023Ownership: 1.366%MPM Bioimpact LLCSold 2,877,037 shares on 11/14/2023Ownership: 8.239%Acadian Asset Management LLCSold 69,040 shares on 11/13/2023Ownership: 0.198%Ronald HuntBought 1,000 shares on 3/23/2023Total: $10 M ($10,000.00/share)View All Insider TransactionsView All Institutional Transactions HARP Stock Analysis - Frequently Asked Questions Should I buy or sell Harpoon Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HARP shares. View HARP analyst ratings or view top-rated stocks. What is Harpoon Therapeutics' stock price target for 2024? 5 analysts have issued 12-month price objectives for Harpoon Therapeutics' stock. Their HARP share price targets range from $13.00 to $45.00. On average, they predict the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 202.9% from the stock's current price. View analysts price targets for HARP or view top-rated stocks among Wall Street analysts. How have HARP shares performed in 2023? Harpoon Therapeutics' stock was trading at $7.2570 at the beginning of the year. Since then, HARP shares have increased by 34.2% and is now trading at $9.74. View the best growth stocks for 2023 here. Are investors shorting Harpoon Therapeutics? Harpoon Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 255,300 shares, an increase of 7.2% from the October 31st total of 238,200 shares. Based on an average daily volume of 156,700 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.9% of the company's stock are short sold. View Harpoon Therapeutics' Short Interest. When is Harpoon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our HARP earnings forecast. How were Harpoon Therapeutics' earnings last quarter? Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($3.09) by $2.63. The company earned $4.45 million during the quarter, compared to analyst estimates of $8.33 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%. When did Harpoon Therapeutics' stock split? Harpoon Therapeutics's stock reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO? 5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend. What other stocks do shareholders of Harpoon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD). When did Harpoon Therapeutics IPO? (HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers. Who are Harpoon Therapeutics' major shareholders? Harpoon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include MPM Bioimpact LLC (8.24%), Kennedy Capital Management LLC (1.37%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Ronald Hunt. View institutional ownership trends. How do I buy shares of Harpoon Therapeutics? Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:HARP) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.